NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--December 15, 2025--
Johnson & Johnson $(JNJ)$ will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21(st) to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team.
Investors and other interested parties can access the webcast/conference call in the following ways:
-- The webcast and presentation material are accessible at Johnson &
Johnson's website www.investor.jnj.com. A replay of the webcast will be
available approximately three hours after the conference call concludes.
-- By telephone: for both "listen-only" participants and those financial
analysts who wish to take part in the question-and-answer portion of the
call, the telephone dial-in number in the U.S. is 877-869-3847. For
participants outside the U.S., the dial-in number is 201-689-8261.
-- A replay of the conference call will be available until approximately
12:00 a.m. on February 4th. The replay dial-in number for U.S.
participants is 877-660-6853. For participants outside the U.S., the
replay dial-in number is 201-612-7415. The replay conference ID number
for all callers is 13757287.
-- The press release will be available at approximately 6:45 a.m. (Eastern
Time) the morning of the conference call.
-- Please refer to www.investor.jnj.com for a complete list of currently
planned earnings webcast/conference calls. Please note the first-quarter
date of Tuesday, April 14th, 2026.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251215079601/en/
CONTACT: Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
(END) Dow Jones Newswires
December 15, 2025 16:27 ET (21:27 GMT)
Comments